A full understanding of the IRA's impact on innovation requires considering not merely the number of new drugs that might come to market after the law's passage but the clinical value those new drugs deliver to patients.
The blockbuster weight loss drugs' access to a key market — older Americans — is limited, as Medicare is banned from covering weight loss drugs as part of the Part D program.
Pfizer is facing a shortage of penicillin due to increased demand and more diagnoses of syphilis, the company said in a letter to its customers this week.